Elikon Venture Research
Investment Thesis
Elikon Venture is a global early-stage biotech investor, founded in 2021, dedicated to addressing unmet clinical needs. Public deal announcements describe the firm as concentrating on early-stage biotech and healthcare opportunities, seeking to partner with entrepreneurs who hold independent intellectual property and leading scientific innovations capable of developing breakthrough products that deliver robust clinical benefit to patients. The firm is repeatedly described as bringing distinctive cross-border insight to the biopharma market, and specializes in connecting its global portfolio companies to China's top-tier industry resources and strategic services (manufacturing, clinical, and commercial partners).
Important caveat: the website provided for this firm (https://elikon.vc/) does not currently resolve (DNS NXDOMAIN, no Wayback Machine snapshot on record), so this research is built entirely from third-party sources — press releases, Crunchbase/PitchBook/Tracxn/Unicorn Nest listings, and news coverage of specific financing rounds. No on-site content (team page, portfolio page, thesis page) could be reviewed directly. Fields below should be treated as directionally reliable but not verified against the firm's own materials.
Sector Focus
Elikon Venture invests exclusively in life sciences / biotech, with a cross-border US-China orientation. Portfolio companies span:
- Precision oncology and lineage-based cancer therapeutics
- CAR-T cell therapy platforms
- mRNA vaccine platforms
- Antibody biotherapeutics and degrader-antibody drug conjugates
- Metabolic and immune-related disease therapeutics
- Surgical robotics for diagnosis and treatment
- Bone, muscle, and joint disease treatments
Stage Focus
Primarily Seed and Series A, with selective participation at Series B and beyond as a follow-on or syndicate participant (e.g., Agibot Medical Technology's Series B). Round data suggests Elikon most often appears as part of a multi-investor syndicate rather than as a sole institutional check-writer.
Check Size
Not disclosed by any source reviewed. Rounds Elikon has participated in range from $18M (Innovac Therapeutics Series Pre-A) to $70-110M (OriCell Therapeutics Series C), but Elikon's individual allocation within these syndicated rounds is not publicly broken out. Treat check size as unknown pending direct confirmation.
Lead Tendency
Mixed. Elikon is described as co-leading CORE Biomedicine's $21M Series A alongside UTokyo Innovation Platform (July 2026), but appears as one of several co-investors (not lead) in Ucello Therapeutics' $25M Series A (led by Matrix Partners China, February 2022) and Agibot Medical Technology's Series B (November 2025, among four new investors).
Recent Activity
- July 2026: Co-led CORE Biomedicine's $21M Series A (with UTokyo Innovation Platform; other participants included InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate, Root Venture Partners)
- November 2025: New investor in Agibot Medical Technology's Series B (alongside Nantong Investment Management, Oriza FoFs, Mingxi Capital)
- Tracxn reports 2 new investments in the trailing 12 months as of its most recent snapshot, consistent with an actively deploying posture
Portfolio Highlights
At least 8-10 disclosed portfolio companies, concentrated in US biotech hubs (Boston/Cambridge area) and China (Shanghai, Chengdu, Suzhou, Guangzhou):
- CORE Biomedicine (Allston, MA) — lineage-based precision oncology, founded by former H3 Biomedicine leaders
- OriCell Therapeutics (Shanghai) — CAR-T cell therapy for solid tumors; raised a $70M+ Series C
- Allorion Therapeutics (Natick, MA) — cancer and autoimmune disease therapeutics
- Angitia Biopharmaceuticals (Guangzhou) — bone, muscle, and joint disease treatments
- Fortitude Biomedicines (Waltham, MA) — antibody biotherapeutics, degrader-ADC platform
- Innovac Therapeutics (Cambridge, MA) — mRNA vaccine platform, founded 2022
- Eccogene (Shanghai) — metabolic and immune-related disease therapeutics
- Ucello Therapeutics (Chengdu/San Diego) — completed $25M Series A in 2022
- Agibot Medical Technology (Suzhou) — surgical robots for diagnosis and treatment
Team
No team roster could be confirmed from the firm's own site. A single LinkedIn profile, Zeen Zhang, lists an association with Elikon Venture (educated at UT Austin's McCombs School of Business, based in Canada), but no confirmed title at the firm was found in public sources. This should be treated as low-confidence and verified directly before outreach.
Decision Process
Unknown — no public source describes whether Elikon operates as a solo GP, small partnership, or investment committee.
Founder Preferences
Public deal language suggests a preference for entrepreneurs with independent, defensible IP and technical/scientific leadership capable of producing clinically differentiated therapeutics, rather than platform or services plays.
Geographic Focus
Cross-border US-China biotech: portfolio companies cluster in the Boston/Cambridge biotech corridor and in Shanghai/Chengdu/Suzhou/Guangzhou, China. Some third-party listings claim a Shanghai, China headquarters; this could not be verified directly (the firm's own site is unreachable) and should be confirmed before relying on it operationally.
Data Quality Note
A separate, seemingly unrelated entity also uses a very similar name ("Elikon Venture" per flaia.org, associated with elekronventures.com, British Virgin Islands, Middle East-focused private equity) — this appears to be a name collision with a different organization and was excluded from this profile. If future research surfaces information matching that Middle East / BVI profile under the "Elikon Venture" name, it should be manually disambiguated against this China/US-biotech-focused entity before merging.